Skip Ribbon Commands
Skip to main content

News

London

Biopharmaceutical company UCB appoints JLL for global real estate services

Extended contract spans 40 countries


​London, Tuesday 11 November – Brussels-based biopharmaceutical company UCB has signed a three year global real estate services agreement with JLL.

 

The agreement spans 40 countries and expands on a mandate awarded in 2011 where JLL was appointed to provide lease administration, transaction management and real estate advisory services. New services added include financial management and project and development services (P&DS). Té​tris Design & Build, JLL's specialist design, fit-out and refurbishment team has also been appointed to work on multiple occupier projects.

"Since 2011 when this client relationship started, we have focused on providing the most efficient corporate solutions framework for UCB's global real estate portfolio. We have already generated €9.5 million in cost savings across Japan, France, Spain, Portugal, The Netherlands and Italy. The largest individual project undertaken to date by JLL was the relocation of UCB's Japanese 2,650 sqm offices in Tokyo. The newly extended contract scope means that we will further build on this and continuously enhance real estate solutions supported by robust project management services." said Eric Orban, UCB Global Client Manager, JLL Corporate Solutions.

"JLL have helped us gain clarity across our global real estate portfolio. This knowledge has permitted us to anticipate lease events and start taking sound and strategic decisions in line with our future business needs. Comparing our various local situations with relevant market intelligence has given us an unprecedented edge in our real estate portfolio management." said Jean-Christophe Donck, Vice-President Site Facilities & Workplace Development, UCB.

Vincent Lottefier, Global Director and CEO Corporate Solutions, Europe, Middle East & Africa for JLL said, "This extended contract epitomises the trend for European headquartered multinational corporates to task a specialist adviser to help them control and manage their commercial real estate across the globe. The client benefit is clear - increased productivity, consistent service and substantial cost savings. We are excited to have been re-appointed to work with UCB and look forward to supporting their global strategic and operational activities."

JLL Corporate Solutions has recently been appointed by multiple global financial services, oil and gas and professional companies. Existing pharmaceutical sector clients include Pfizer, GSK, AstraZeneca and Sanofi.

Headquartered in Brussels, Belgium, UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in approximately 40 countries, the company generated revenue of €3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB)